500 drug approval records drawn from four major regulatory jurisdictions: China (NMPA), United States (FDA), European Union (EMA), and Japan (PMDA), with approximately 100 records per region. The dataset was created by PatSnap and was last updated on the platform in April 2026. It is designed for comparative regulatory analysis and temporal modeling of the global pharmaceutical approval landscape.
Use Cases
- Conduct comparative regulatory analysis based on the four-jurisdiction coverage.
- Model approval timelines and delays based on the temporal data mentioned in the description.
- Analyze regional differences in pharmaceutical market access based on the balanced representation of China, US, EU, and Japan.
Strengths
- Contains 500 drug approval records.
- Provides balanced representation across four major regulatory jurisdictions, with approximately 100 records per region.
Limitations
- Column-level documentation is absent; field semantics must be inferred after download.
- Row count is unknown, which may limit suitability assessment.
Provenance
- Source
- PatSnap
- Freshness
- Last updated 2026-04-22 09:21:05; freshness should be verified.
- Geography
- China, United States, European Union, Japan